Compare VTMX & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTMX | SRPT |
|---|---|---|
| Founded | 1998 | 1980 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2023 | 2000 |
| Metric | VTMX | SRPT |
|---|---|---|
| Price | $34.39 | $17.12 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 29 |
| Target Price | ★ $40.00 | $25.85 |
| AVG Volume (30 Days) | 126.2K | ★ 2.7M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | $12.22 | N/A |
| Revenue Next Year | $11.52 | N/A |
| P/E Ratio | $47.91 | ★ $5.78 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $24.99 | $10.42 |
| 52 Week High | $37.41 | $43.92 |
| Indicator | VTMX | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 33.75 |
| Support Level | $33.84 | $16.09 |
| Resistance Level | $36.96 | $19.32 |
| Average True Range (ATR) | 1.19 | 1.14 |
| MACD | -0.20 | -0.49 |
| Stochastic Oscillator | 50.96 | 7.59 |
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.